Raymedica disc update
This article was originally published in The Gray Sheet
Executive Summary
Investigational device exemption for the PDN-Solo pivotal trial is pushed back to June, due to a longer-than-expected pilot study. With patient enrollment now scheduled to start by the end of Q4, the firm anticipates receiving PMA approval in 2007, rather than the second half of 2006. The prosthetic disc nucleus device, which previously was priced in comparison to spinal fusion at $4,000, now will be priced in line with other artificial discs at $6,000 and will fall under the new CPT code for spinal arthrodesis, expected in the spring. The company anticipates selling up to 360,000 devices upon release (1"The Gray Sheet" Oct. 27, 2003, p. 25)...
You may also be interested in...
Lumbar Disc Developers Hold Their Own With Orthopedic Giants
Raymedica and Interpore Cross are readying internally-developed artificial spinal disc offerings for U.S. market entry behind J&J/DePuy Acromed, Medtronic/Sofamor Danek and Synthes-Stratec - three companies competing through recent acquisitions
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.